Tempest Therapeutics Stock Analysis
| TPST Stock | USD 0.93 0.00 0.000001% |
Tempest Therapeutics is undervalued with Real Value of 5.34 and Target Price of 18.75. The main objective of Tempest Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Tempest Therapeutics is worth, separate from its market price. There are two main types of Tempest Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Tempest Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Tempest Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Tempest Stock trading window is adjusted to America/New York timezone.
Tempest |
Tempest Stock Analysis Notes
About 16.0% of the company shares are owned by institutional investors. The book value of Tempest Therapeutics was at this time reported as 0.43. The company recorded a loss per share of 1.53. Tempest Therapeutics last dividend was issued on the 10th of December 2018. The entity had 1:15 split on the 28th of June 2021. Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc. Tempest Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people. To find out more about Tempest Therapeutics contact LLM JD at 415 798 8589 or learn more at https://www.tempesttx.com.Tempest Therapeutics Investment Alerts
| Tempest Therapeutics has some characteristics of a very speculative penny stock | |
| Tempest Therapeutics had very high historical volatility over the last 90 days | |
| Tempest Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (29.49 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Tempest Therapeutics currently holds about 51.62 M in cash with (27.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.95, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Tempest Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Tempest Granted Fast Track Designation from the U.S. ... |
Tempest Therapeutics Upcoming and Recent Events
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Tempest Largest EPS Surprises
Earnings surprises can significantly impact Tempest Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-06 | 2024-09-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2023-11-08 | 2023-09-30 | -0.57 | -0.48 | 0.09 | 15 | ||
2023-05-10 | 2023-03-31 | -0.64 | -0.55 | 0.09 | 14 |
Tempest Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Virtu Financial Llc | 2024-12-31 | 43.1 K | State Street Corp | 2024-09-30 | 41.5 K | Advisor Group Holdings, Inc. | 2024-12-31 | 25.4 K | Boothbay Fund Management, Llc | 2024-09-30 | 24.6 K | Xtx Topco Ltd | 2024-09-30 | 24 K | Two Sigma Investments Llc | 2024-09-30 | 22.9 K | Northern Trust Corp | 2024-09-30 | 20.4 K | Simplex Trading, Llc | 2024-09-30 | 13.1 K | Ground Swell Capital, Llc | 2024-09-30 | 10.9 K | Blackrock Inc | 2024-09-30 | 551.6 K | Fmr Inc | 2024-09-30 | 431.9 K |
Tempest Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 40.59 M.Tempest Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.66) | (0.69) | |
| Return On Capital Employed | (0.79) | (0.83) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (1.27) | (1.33) |
Management Efficiency
Tempest Therapeutics has return on total asset (ROA) of (0.7701) % which means that it has lost $0.7701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9189) %, meaning that it created substantial loss on money invested by shareholders. Tempest Therapeutics' management efficiency ratios could be used to measure how well Tempest Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.69 in 2025. Return On Capital Employed is likely to drop to -0.83 in 2025. Liabilities And Stockholders Equity is likely to gain to about 70.9 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 9.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.00 | 1.90 | |
| Tangible Book Value Per Share | 2.00 | 1.90 | |
| Enterprise Value Over EBITDA | (1.54) | (1.62) | |
| Price Book Value Ratio | 2.91 | 3.14 | |
| Enterprise Value Multiple | (1.54) | (1.62) | |
| Price Fair Value | 2.91 | 3.14 | |
| Enterprise Value | 56.7 M | 44.6 M |
Leadership at Tempest Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Technical Drivers
As of the 17th of February 2025, Tempest Therapeutics has the Risk Adjusted Performance of (0.02), variance of 19.34, and Coefficient Of Variation of (2,991). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Tempest Therapeutics, as well as the relationship between them.Tempest Therapeutics Price Movement Analysis
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Tempest Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Tempest Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Tempest Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Tempest Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Tempest Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Tempest Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Tempest Therapeutics Outstanding Bonds
Tempest Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Tempest Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Tempest bonds can be classified according to their maturity, which is the date when Tempest Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TELUS P 37 Corp BondUS87971MBF95 | View | |
| TELUS P 46 Corp BondUS87971MBH51 | View | |
| TELUS P 28 Corp BondUS87971MBD48 | View | |
| TCN 34 13 MAY 32 Corp BondUS87971MBW29 | View |
Tempest Therapeutics Predictive Daily Indicators
Tempest Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Tempest Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0319 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.93 | |||
| Day Typical Price | 0.93 | |||
| Market Facilitation Index | 0.03 | |||
| Price Action Indicator | 0.005 | |||
| Relative Strength Index | 53.27 |
Tempest Therapeutics Forecast Models
Tempest Therapeutics' time-series forecasting models are one of many Tempest Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Tempest Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Tempest Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Tempest Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Tempest shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Tempest Therapeutics. By using and applying Tempest Stock analysis, traders can create a robust methodology for identifying Tempest entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (329.74) | (346.23) | |
| Operating Profit Margin | (79.85) | (83.84) | |
| Net Loss | (329.71) | (346.20) | |
| Gross Profit Margin | 0.81 | 0.86 |
Current Tempest Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Tempest analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Tempest analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 18.75 | Strong Buy | 5 | Odds |
Most Tempest analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Tempest stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Tempest Therapeutics, talking to its executives and customers, or listening to Tempest conference calls.
Tempest Stock Analysis Indicators
Tempest Therapeutics stock analysis indicators help investors evaluate how Tempest Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Tempest Therapeutics shares will generate the highest return on investment. By understating and applying Tempest Therapeutics stock analysis, traders can identify Tempest Therapeutics position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 31.6 M | |
| Long Term Debt | 6.3 M | |
| Common Stock Shares Outstanding | 15.4 M | |
| Total Stockholder Equity | 26.8 M | |
| Property Plant And Equipment Net | 10.8 M | |
| Cash And Short Term Investments | 39.2 M | |
| Cash | 39.2 M | |
| Accounts Payable | 845 K | |
| Net Debt | -18.6 M | |
| 50 Day M A | 0.8837 | |
| Total Current Liabilities | 9.4 M | |
| Other Operating Expenses | 29.2 M | |
| Non Current Assets Total | 11.2 M | |
| Non Currrent Assets Other | 448 K | |
| Stock Based Compensation | 2.5 M |
Additional Tools for Tempest Stock Analysis
When running Tempest Therapeutics' price analysis, check to measure Tempest Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tempest Therapeutics is operating at the current time. Most of Tempest Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tempest Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tempest Therapeutics' price. Additionally, you may evaluate how the addition of Tempest Therapeutics to your portfolios can decrease your overall portfolio volatility.